Pediatric oncology enters an era of precision medicine.

[1]  O. Delattre,et al.  Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors , 2017, Pediatric blood & cancer.

[2]  P. Raman,et al.  Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome , 2016, PLoS genetics.

[3]  David T. W. Jones,et al.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.

[4]  R. Gray,et al.  Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis , 2016 .

[5]  Tao Wang,et al.  Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.

[6]  B. Crompton,et al.  Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. , 2016, JAMA oncology.

[7]  Roman Rouzier,et al.  Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials , 2015, Journal of the National Cancer Institute.

[8]  Nallasivam Palanisamy,et al.  Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.

[9]  Gudrun Schleiermacher,et al.  Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations , 2015, Nature Genetics.

[10]  Sven Rahmann,et al.  Mutational dynamics between primary and relapse neuroblastomas , 2015, Nature Genetics.

[11]  Yingdong Zhao,et al.  Application of molecular profiling in clinical trials for advanced metastatic cancers. , 2015, Journal of the National Cancer Institute.

[12]  F. Speleman,et al.  Emergence of new ALK mutations at relapse of neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Heerema,et al.  Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031 , 2014, Leukemia.

[14]  J. Maris,et al.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.

[15]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[16]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[17]  N. Heerema,et al.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Trevor J Pugh,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .